SpringerLink
Log in

Disease Modification in Crohn’s Disease

  • Chapter
  • First Online:
Biomarkers in Inflammatory Bowel Diseases

  • 633 Accesses

Abstract

Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract (GIT) that evolves in a relapsing and remitting pattern. CD is a destructive disease that can result in progressive bowel damage and ultimately disability. It mainly affects young adults, causes morbidity, and impacts on quality of life. The majority of patients with CD initially present with an inflammatory phenotype at diagnosis, but over time various complications that result in tissue damage can occur such as strictures, abscesses, and fistulae, which often require surgery. The functional correlate of tissue damage is disability which may develop over time. Current management strategies therefore base their premise on “treating to target” with the aim of achieving deep and prolonged disease remission, thereby preventing tissue damage and disability. The following sections will address the identification and assessment of tissue damage and how we can evaluate disability in CD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 85.59
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 106.99
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010/07/20. 2010;139(4):1147–55.

    Article  Google Scholar 

  2. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis [Internet]. 2011/05/12. 2011;17(6):1415–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21560202.

  3. Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing collateral damage in Crohn’s disease: the Lémann index. J Crohns Colitis. 2016;10(4):495–500.

    Article  Google Scholar 

  4. Pariente B, Mary J-Y, Danese S, Chowers Y, De Cruz P, D’Haens G, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148(1):52–63.e3.

    Article  Google Scholar 

  5. Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11(3):274–80.

    PubMed  Google Scholar 

  6. Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, et al. Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn’s disease. J Crohns Colitis. 2015;9(8):633–9.

    Article  Google Scholar 

  7. https://www.cdc.gov/hrqol/index.htm. Health related quality of life.

  8. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96(3):804–10.

    Article  CAS  Google Scholar 

  9. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1246–56.e6.

    Article  Google Scholar 

  10. Jelsness-Jørgensen L-P, Bernklev T, Henriksen M, Torp R, Moum BA. Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2011 [cited 2017 May 18];33(1):106–14. Available from: http://doi.wiley.com/10.1111/j.1365-2036.2010.04498.x.

    Article  Google Scholar 

  11. Romberg-Camps MJL, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MAM, Kester ADM, Engels LGJB, et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis [Internet]. 2010 [cited 2017 May 18];16(12):2137–47. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00054725-201012000-00020.

  12. Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol [Internet]. 2007 [cited 2017 May 18];13(14):2089–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17465453.

    Article  CAS  Google Scholar 

  13. Graff LA, Vincent N, Walker JR, Clara I, Carr R, Ediger J, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis [Internet]. 2011 [cited 2017 May 18];17(9):1882–9. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00054725-201109000-00006.

  14. Vogelaar L, van’t Spijker A, van Tilburg AJP, Kuipers EJ, Timman R, van der Woude CJ. Determinants of fatigue in Crohn’s disease patients. Eur J Gastroenterol Hepatol [Internet]. 2013 [cited 2017 May 18];25(2):246–51. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042737-201302000-00018.

  15. Moser G. Depression and anxiety in inflammatory bowel disease. Gastroenterol Hepatol [Internet]. 2009 [cited 2017 May 18];32 Suppl 2:9–12. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0210570509725993.

  16. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol [Internet]. 2002 [cited 2017 May 18];97(2):389–96. Available from: http://www.nature.com/doifinder/10.1111/j.1572-0241.2002.05475.x.

    Article  Google Scholar 

  17. Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, et al. Predictors of temporary and permanent work disability in patients with inflammatory bowel disease. Inflamm Bowel Dis [Internet]. 2013 [cited 2017 Jun 7];19(4):847–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23446333.

    Article  Google Scholar 

  18. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut [Internet]. 2013 [cited 2017 Jan 9];62(3):368–75. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2012-302311.

  19. Coenen M, Cieza A, Stamm TA, Amann E, Kollerits B, Stucki G. Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther. 2006;8(4):R84.

    Article  Google Scholar 

  20. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, et al. Disability in inflammatory bowel diseases: develo** ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis [Internet]. 2009/07/18. 2010;16(1):15–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19610077.

    Article  Google Scholar 

  21. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut [Internet]. 2012 [cited 2012 Dec 7];61(2):241–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3245899&tool=pmcentrez&rendertype=abstract.

  22. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut. 2017;66(4):588–96.

    Article  Google Scholar 

  23. Peyrin-Biroulet L, Gower-Rousseau C. The IBD disability index should become a major secondary endpoint in clinical practice and in clinical trials. J Crohns Colitis [Internet]. 2016 [cited 2017 May 16];10(12):1375–7. Available from: https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1093/ecco-jcc/jjw156.

    Article  Google Scholar 

  24. Disability, poverty and development. World Hosp Health Serv [Internet]. 2002 [cited 2017 May 16];38(1):21–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12221831.

  25. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol [Internet]. 2016 [cited 2017 May 16];14(3):348–354.e17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26071941.

  26. Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, et al. Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis [Internet]. 2017 [cited 2017 May 15];23(3):333–40. Available from: http://insights.ovid.com/crossref?an=00054725-201703000-00001.

    Article  Google Scholar 

  27. Peyrin-Biroulet L, Reinisch W, Colombel J-F, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63(1):88–95.

    Article  Google Scholar 

  28. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis [Internet]. 2011 [cited 2013 Jan 21];5(5):477–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21939925.

    Article  Google Scholar 

  29. Colombel J-F, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. Deep remission: a new concept? Dig Dis. 2012;30(Suppl 3):107–11.

    Article  Google Scholar 

  30. Colombel J, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, et al. Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):414–422.e5.

    Article  CAS  Google Scholar 

  31. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - A SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734–46.

    Article  CAS  Google Scholar 

  32. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38.

    Article  CAS  Google Scholar 

  33. Colombel J-F, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351–361.e5.

    Article  Google Scholar 

  34. Peyrin-Biroulet L. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. Am J Gastroenterol. 2013;108(5):859–60.

    Article  Google Scholar 

  35. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65-5.

    Article  Google Scholar 

  36. Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74.e1.

    Article  Google Scholar 

  37. Peyrin-Biroulet L, Danese S. Early combined immunosuppression in Crohn’s disease: acting rather than REACTing. Gastroenterology. 2016;150(4):1040–1.

    Article  Google Scholar 

  38. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825–34.

    Article  Google Scholar 

  39. Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;371(9613):660–7.

    Google Scholar 

  40. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis [Internet]. 2010/12/03. 2010;4(1):63–101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21122490.

  41. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol [Internet]. 2013 [cited 2013 Apr 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23458890.

  42. Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis [Internet]. 2012 [cited 2013 Jan 21];30 Suppl 3:67–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23295694.

  43. Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel J-F, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716–30.

    Article  CAS  Google Scholar 

  44. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, et al. Development of an index to define overall disease severity in IBD. Gut. 2018;67(2):244–54.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Gastroenterology, Ulster Hospital, Belfast, UK

    Patrick B. Allen

  2. South Eastern Health and Social Care Trust, Belfast, NI, UK

    Patrick B. Allen

  3. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France

    Laurent Peyrin-Biroulet

Authors
  1. Patrick B. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurent Peyrin-Biroulet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Vincent’s Hospital, The University of Melbourne, Melbourne, VIC, Australia

    Nik Sheng Ding

  2. Austin Health, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Allen, P.B., Peyrin-Biroulet, L. (2019). Disease Modification in Crohn’s Disease. In: Sheng Ding, N., De Cruz, P. (eds) Biomarkers in Inflammatory Bowel Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-11446-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11446-6_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11445-9

  • Online ISBN: 978-3-030-11446-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation